TREG-cell therapies for autoimmune rheumatic diseases - PubMed (original) (raw)

Review

TREG-cell therapies for autoimmune rheumatic diseases

Makoto Miyara et al. Nat Rev Rheumatol. 2014 Sep.

Abstract

Naturally occurring Foxp3(+)CD25(+)CD4(+) regulatory T (TREG) cells maintain immunological self-tolerance and prevent a variety of autoimmune diseases, including rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus. In animal models of rheumatic disease, autoimmune responses can be controlled by re-establishing the T-cell balance in favour of TREG cells. Here we discuss three potential strategies for the clinical use of TREG cells to treat autoimmune rheumatic disease: expansion of self-antigen-specific natural TREG cells in vivo; propagation of antigen-specific natural TREG cells ex vivo, by in vitro antigenic stimulation, and subsequent transfer back into the host; or conversion of antigen-specific conventional T cells into TREG cells in vivo or ex vivo. These strategies require depletion of the effector T cells that mediate autoimmunity before initiating TREG-cell-based therapies. Immunotherapies that target TREG cells, and the balance of TREG cells and autoreactive T cells, are therefore an important modality for the treatment of autoimmune rheumatic disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nature. 2007 Apr 5;446(7136):685-9 - PubMed
    1. Eur J Immunol. 2013 Aug;43(8):2043-54 - PubMed
    1. Eur J Immunol. 2009 Jun;39(6):1466-71 - PubMed
    1. Immunol Cell Biol. 2011 Mar;89(3):346-51 - PubMed
    1. Int Immunol. 1998 Dec;10(12):1969-80 - PubMed

Publication types

MeSH terms

LinkOut - more resources